Transforming Growth Factor Beta 1-induced Changes in Cell Migration, Proliferation, and Angiogenesis in the Chicken Chorioallantoic Membrane
Overview
Affiliations
Application of TGF beta 1 (10-100 ng) to the chicken chorioallantoic membrane (CAM) for 72 h resulted in a dose-dependent, gross angiogenic response. The vascular effects induced by TGF beta 1 were qualitatively different than those induced by maximal doses of basic FGF (bFGF) (500 ng). While TGF beta 1 induced the formation of large blood vessels by 72 h, bFGF induced primarily small blood vessels. Histologic analysis revealed that TGF beta 1 stimulated pleiotropic cellular responses in the CAM. Increases in fibroblast and epithelial cell density in the area of TGF beta 1 delivery were observed as early as 4 h after TGF beta 1 treatment. By 8 h, these cell types also demonstrated altered morphology and marked inhibition of proliferation as evidenced by 3H-thymidine labeling. Thus, the TGF beta 1-stimulated accumulation of these cell types was the result of cellular chemotaxis from peripheral areas into the area of TGF beta 1 delivery. Microscopic angiogenesis in the form of capillary sprouts and increased endothelial cell density first became evident at 16 h. By 24 h, capillary cords appeared within the mesenchyme of the CAM, extending towards the point of TGF beta 1 delivery. 3H-thymidine labeling revealed that the growth of these capillary cords was due to endothelial cell proliferation. Finally, perivascular mononuclear inflammation did not become evident until 48 h of treatment, and its presence correlated spatially and temporally with the gross and histological remodelling of newly formed capillary cords into larger blood vessels. In summary, these data suggest that, in the chicken CAM, TGF beta 1 initiates a sequence of cellular responses that results in growth inhibition, cellular accumulation through migration, and microvascular angiogenesis.
Standardization to Characterize the Complexity of Vessel Network Using the Aortic Ring Model.
Wolint P, Hofmann S, von Atzigen J, Boni R, Miescher I, Giovanoli P Int J Mol Sci. 2025; 26(1.
PMID: 39796147 PMC: 11719671. DOI: 10.3390/ijms26010291.
Current Challenges in the Development of Platelet-Rich Plasma-Based Therapies.
Mercader-Ruiz J, Beitia M, Delgado D, Sanchez P, Porras B, Gimeno I Biomed Res Int. 2024; 2024:6444120.
PMID: 39157212 PMC: 11329313. DOI: 10.1155/2024/6444120.
Mercader Ruiz J, Beitia M, Delgado D, Sanchez P, Arnaiz M, de Dicastillo L Int J Mol Sci. 2023; 24(18).
PMID: 37762114 PMC: 10530784. DOI: 10.3390/ijms241813811.
Platelet P2Y signalling pathway in the dysregulated immune response during sepsis.
Amoafo E, Entsie P, Kang Y, Canobbio I, Liverani E Br J Pharmacol. 2023; 181(4):532-546.
PMID: 37525937 PMC: 10830899. DOI: 10.1111/bph.16207.
Hsu H, Ko P, Peng C, Cheng Y, Wu H, Tung Y Mater Today Bio. 2023; 21:100703.
PMID: 37483382 PMC: 10359940. DOI: 10.1016/j.mtbio.2023.100703.